Financial

Retension Pharmaceuticals Closes $10.4 Million Oversubscribed Series A to Fund Clinical Trials for Patients Suffering from Resistant and Uncontrolled Hypertension

FALLS CHURCH, Va.–(BUSINESS WIRE)–Retension Pharmaceuticals, Inc. is pleased to announce the successful closing of its Series A $10.4 million financing round to initiate a well-powered and controlled Phase 2 clinical study in patients with hypertension uncontrolled on two or more antihypertensives. Inhibition of PDE5 is a long-desired mechanism for enhancing NO-based […]

B-Secur and FIRMINIQ Join Forces to Transform Cardiovascular Health Management

PLANO, Texas & BELFAST, Northern Ireland–(BUSINESS WIRE)–B-Secur, a leader in advanced biosensing technology, and FIRMINIQ, a software product development company specializing in connected health, are proud to announce a strategic partnership aimed at transforming cardiovascular health management globally. “Our new alliance with FIRMINIQ represents a significant leap forward in how we […]

Jupiter Endovascular Exits Stealth With $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism

August 15, 2024 10:00 AM Eastern Daylight Time MENLO PARK, Calif.–(BUSINESS WIRE)–Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a […]

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2024 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session.

Radiaction Medical Establishes Medical Advisory Board

TEL AVIV, Israel–(BUSINESS WIRE)–Radiaction Medical, LTD (“Radiaction”), a medical device company, has announced the formation of its U.S. Medical Advisory Board (MAB). The MAB will provide invaluable counsel and expertise to the company’s executive team, bolstering Radiaction’s mission to deliver comprehensive radiation protection to all medical staff involved in interventional […]

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

August 12, 2024 04:01 PM Eastern Daylight Time MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed […]